The small macrocyclic compound lorlatinib (product name PF-06463922) is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) originally developed to inhibit ALK mutant forms causing resistance to first- and second-generation ALK-TKIs (e.g., crizotinib, ceritinib, alectinib or brigatinib) in patients with advanced non-small-cell lung cancer (NSCLC) [1,2,3,4,5,6]. This evidence concerns the gene ALK and non-small cell lung carcinoma.